All In Biotech

Drug Trial Radar · NCT04581473

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Oct 23, 2020

Primary completion

Oct 18, 2024

Study completion Jun 30, 2038

Sponsor

Lead sponsor
CARsgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute; Fudan University
First posted
Oct 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer

Conditions

  • Gastric Adenocarcinoma
  • Pancreatic Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • CT041 autologous CAR T-cell injectionDrug

    Up to 3 times CT041 autologous CAR T-cell injection infusion

  • Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)Drug

    Physician's choice of any BSC listed above

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence of Treatment Related adverse events (AEs)Time frame: Up to 18 months
  2. Phase Ib: Identification of Maximum Tolerated Dose (MTD)Time frame: day1-day28
  3. Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's ChoiceTime frame: Up to 24 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangzhou, China

  • Harbin medical university Affiliated Cancer Hospital

    Harbin, Heilongjia, China

  • Henan Tumor Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine

    Shanghai, Shanghai Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanghai Zhongshan Hospital

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hanzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.